Oryzon participates in a R&D European consortium in Parkinson’s disease
Oryzon nominates bispecific LSD1/MAOB inhibitor as drug candidate to enter preclinical development in Huntington´s Disease
Oryzon to Present at 4th CHI X-Gen Congress, Epigenetics, Targets and Therapies on March 6
Oryzon will launch its first product onto the market
Oryzon to Present at CTAD 2010 Conference in Toulouse, France.
Contact
Oryzon Genomics Sant Ferran 74 08940 Cornellà de Llobregat, Barcelona SPAIN T: (+34) 93 515 1313 F: (+34) 93 377 4028 info@oryzon.com Access to R & D headquarters of ORYZON Buses 67, 68, 93 y 95 Metro Line 5 More information Ferrocarrils de la Generalitat de Catalunya – Almeda station Five minutes from El Prat International airport Next to the exit number 15 of the Ronda de Dalt and 16A of Ronda Litoral
Contact form